Table 3.
Distribution of IgM/IgG combinations in second-round follow-up subjects.
| IgM/IgG double-negative | IgM single-positive | IgG single-positive | IgM/IgG double-positive | P | |
|---|---|---|---|---|---|
| Overall | 54(16.98) | 9(2.83) | 199(62.58) | 56(17.61) | |
| Gender | 0.644 | ||||
| male | 29(19.33) | 5(3.33) | 92(61.33) | 24(16.00) | |
| female | 25(14.88) | 4(2.38) | 107(63.69) | 32(19.05) | |
| Age (ys) | 0.044* | ||||
| <20 | 8(47.06) | 0(0) | 8(47.06) | 1(5.88) | |
| 20~ | 8(25.00) | 1(3.13) | 16(50.00) | 7(21.88) | |
| 30~ | 14(17.72) | 4(5.06) | 48(60.76) | 13(16.46) | |
| 40~ | 8(14.81) | 1(1.85) | 31(57.41) | 14(25.93) | |
| 50~ | 5(6.76) | 2(2.7) | 56(75.68) | 11(14.86) | |
| ≥60 | 11(17.74) | 1(1.61) | 40(64.52) | 10(16.13) | |
| Severity of disease | <0.001*** | ||||
| Asymptomatic type | 28(30.43) | 2(2.17) | 47(51.09) | 15(16.4) | |
| Mild type | 8(13.33) | 2(3.33) | 39(65.00) | 11(18.34) | |
| Normal type | 18(11.11) | 5(3.09) | 111(68.52) | 28(17.28) | |
| Severe/Critical type | 0(0) | 0(0) | 4(50.00) | 4(50.00) | |
| SARS-CoV-2 vaccination | 0.318 | ||||
| Unvaccinated | 50(18.25) | 8(2.92) | 171(62.41) | 45(16.42) | |
| Vaccinated | 4(9.09) | 1(2.27) | 28(63.64) | 11(25.00) |
P < 0.05 represents significant difference. *p < 0.05; ***p < 0.001.